Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: Role of different tropism testing results and of concomitant treatments

Barbara Rossetti, Claudia Bianco, Lara Ines Bellazzi, Bianca Bruzzone, Grazia Colao, Paola Corsi, Laura Monno, Gabriella Pagano, Stefania Paolucci, Grazia Punzi, Maurizio Setti, Maurizio Zazzi, Andrea De Luca

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We assessed the immunovirological response to antiretroviral regimens containing maraviroc in HIV-infected viremic patients with viral tropism predicted by different assays. We selected antiretroviral treatment-experienced HIV-1-infected patients initiating regimens containing maraviroc after different phenotypic or genotypic viral tropism assays, with at least one HIV-1 RNA determination during follow-up. Survival analysis was employed to assess the virological response as time to HIV-1 RNA 10 higher: HR 1.29, 95% CI 1.05-1.60) and concomitant therapy with enfuvirtide (HR 2.05, 0.96-4.39) but not tropism assay results. Of 17 patients with baseline R5-tropic virus and available tropism results while viremic during follow-up on maraviroc, seven (41%) showed a tropism switch to non-R5 virus. A significant proportion of experienced patients treated with regimens containing maraviroc achieved virological response. The tropism test type used was not associated with immunovirological response and concomitant treatment with enfuvirtide increased the chance of immunological response. More than half of virological failures with maraviroc were not accompanied by tropism switch.

Original languageEnglish
Pages (from-to)17-24
Number of pages8
JournalAIDS Research and Human Retroviruses
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Tropism
HIV-1
Viral Tropism
RNA
Viruses
Therapeutics
Survival Analysis
maraviroc
HIV

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases
  • Medicine(all)

Cite this

Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice : Role of different tropism testing results and of concomitant treatments. / Rossetti, Barbara; Bianco, Claudia; Bellazzi, Lara Ines; Bruzzone, Bianca; Colao, Grazia; Corsi, Paola; Monno, Laura; Pagano, Gabriella; Paolucci, Stefania; Punzi, Grazia; Setti, Maurizio; Zazzi, Maurizio; De Luca, Andrea.

In: AIDS Research and Human Retroviruses, Vol. 30, No. 1, 01.01.2014, p. 17-24.

Research output: Contribution to journalArticle

Rossetti, Barbara ; Bianco, Claudia ; Bellazzi, Lara Ines ; Bruzzone, Bianca ; Colao, Grazia ; Corsi, Paola ; Monno, Laura ; Pagano, Gabriella ; Paolucci, Stefania ; Punzi, Grazia ; Setti, Maurizio ; Zazzi, Maurizio ; De Luca, Andrea. / Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice : Role of different tropism testing results and of concomitant treatments. In: AIDS Research and Human Retroviruses. 2014 ; Vol. 30, No. 1. pp. 17-24.
@article{e919742f446b45e082ada2a454b868bc,
title = "Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: Role of different tropism testing results and of concomitant treatments",
abstract = "We assessed the immunovirological response to antiretroviral regimens containing maraviroc in HIV-infected viremic patients with viral tropism predicted by different assays. We selected antiretroviral treatment-experienced HIV-1-infected patients initiating regimens containing maraviroc after different phenotypic or genotypic viral tropism assays, with at least one HIV-1 RNA determination during follow-up. Survival analysis was employed to assess the virological response as time to HIV-1 RNA 10 higher: HR 1.29, 95{\%} CI 1.05-1.60) and concomitant therapy with enfuvirtide (HR 2.05, 0.96-4.39) but not tropism assay results. Of 17 patients with baseline R5-tropic virus and available tropism results while viremic during follow-up on maraviroc, seven (41{\%}) showed a tropism switch to non-R5 virus. A significant proportion of experienced patients treated with regimens containing maraviroc achieved virological response. The tropism test type used was not associated with immunovirological response and concomitant treatment with enfuvirtide increased the chance of immunological response. More than half of virological failures with maraviroc were not accompanied by tropism switch.",
author = "Barbara Rossetti and Claudia Bianco and Bellazzi, {Lara Ines} and Bianca Bruzzone and Grazia Colao and Paola Corsi and Laura Monno and Gabriella Pagano and Stefania Paolucci and Grazia Punzi and Maurizio Setti and Maurizio Zazzi and {De Luca}, Andrea",
year = "2014",
month = "1",
day = "1",
doi = "10.1089/aid.2012.0235",
language = "English",
volume = "30",
pages = "17--24",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice

T2 - Role of different tropism testing results and of concomitant treatments

AU - Rossetti, Barbara

AU - Bianco, Claudia

AU - Bellazzi, Lara Ines

AU - Bruzzone, Bianca

AU - Colao, Grazia

AU - Corsi, Paola

AU - Monno, Laura

AU - Pagano, Gabriella

AU - Paolucci, Stefania

AU - Punzi, Grazia

AU - Setti, Maurizio

AU - Zazzi, Maurizio

AU - De Luca, Andrea

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We assessed the immunovirological response to antiretroviral regimens containing maraviroc in HIV-infected viremic patients with viral tropism predicted by different assays. We selected antiretroviral treatment-experienced HIV-1-infected patients initiating regimens containing maraviroc after different phenotypic or genotypic viral tropism assays, with at least one HIV-1 RNA determination during follow-up. Survival analysis was employed to assess the virological response as time to HIV-1 RNA 10 higher: HR 1.29, 95% CI 1.05-1.60) and concomitant therapy with enfuvirtide (HR 2.05, 0.96-4.39) but not tropism assay results. Of 17 patients with baseline R5-tropic virus and available tropism results while viremic during follow-up on maraviroc, seven (41%) showed a tropism switch to non-R5 virus. A significant proportion of experienced patients treated with regimens containing maraviroc achieved virological response. The tropism test type used was not associated with immunovirological response and concomitant treatment with enfuvirtide increased the chance of immunological response. More than half of virological failures with maraviroc were not accompanied by tropism switch.

AB - We assessed the immunovirological response to antiretroviral regimens containing maraviroc in HIV-infected viremic patients with viral tropism predicted by different assays. We selected antiretroviral treatment-experienced HIV-1-infected patients initiating regimens containing maraviroc after different phenotypic or genotypic viral tropism assays, with at least one HIV-1 RNA determination during follow-up. Survival analysis was employed to assess the virological response as time to HIV-1 RNA 10 higher: HR 1.29, 95% CI 1.05-1.60) and concomitant therapy with enfuvirtide (HR 2.05, 0.96-4.39) but not tropism assay results. Of 17 patients with baseline R5-tropic virus and available tropism results while viremic during follow-up on maraviroc, seven (41%) showed a tropism switch to non-R5 virus. A significant proportion of experienced patients treated with regimens containing maraviroc achieved virological response. The tropism test type used was not associated with immunovirological response and concomitant treatment with enfuvirtide increased the chance of immunological response. More than half of virological failures with maraviroc were not accompanied by tropism switch.

UR - http://www.scopus.com/inward/record.url?scp=84891778812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891778812&partnerID=8YFLogxK

U2 - 10.1089/aid.2012.0235

DO - 10.1089/aid.2012.0235

M3 - Article

C2 - 23971941

AN - SCOPUS:84891778812

VL - 30

SP - 17

EP - 24

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 1

ER -